In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy

Journal of Nuclear Medicine

Volumn 53, Issue 4, 2012, Pages 647-654

  Sorensen, Annette ^a   Mairs, Robert J ^b   Braidwood, Lynne ^c   Joyce, Craig ^a   Conner, Joe ^c   Pimlott, Sally ^d   Brown, Moira ^c   Boyd, Marie ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Crusade Laboratories Limited   (United Kingdom)

^d NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

131I MIBG; Cancer; Gene transfer; HSV1716; Targeted radiotherapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; HSV 1716;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; GENE EXPRESSION SYSTEM; GENETIC TRANSFECTION; GLIOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NORADRENALINE TRANSPORTER GENE; ONCOLYTIC VIROTHERAPY; PLASMID; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS RECOMBINANT;

3-IODOBENZYLGUANIDINE; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; DNA, RECOMBINANT; GENE TRANSFER TECHNIQUES; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; ONCOLYTIC VIRUSES; SEQUENCE DELETION; TIME FACTORS;

EID: 84859416829     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.090886     Document Type: Article

References (39)

1. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 2006;13:975-992. (Pubitemid 44564734)
2. Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother. 2009;9:505-517.
3. Cassady KA, Parker JN. Herpesvirus vectors for therapy of brain tumours. Open Virol J. 2010;4:103-108.
4. Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther. 2009;17:1125-1135.
5. Kanai R, Hiroaki W, Tooba C, Rabkin SD. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol. 2010;6:619-634.
6. MacLean AR, Ul-Fareed M, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a'sequence. J Gen Virol. 1991;72:631-639.
7. Brown SM, Harland J, Maclean AR, Podlech J, Clements JB. Cell type and cell state determine differential in vitro growth of non virulent ICP34.5-negative herpes simplex virus. J Gen Virol. 1994;75:2367-2377. (Pubitemid 24282251)
8. McKie EA, Brown SM, MacLean AR, Graham DI. Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy. Neuropathol Appl Neurobiol. 1998;24:367-372. (Pubitemid 28479482)
9. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM. Treatment of experimental subcutaneous human melanoma with a replication restricted herpes simplex mutant. J Invest Dermatol. 1997;108:933-937. (Pubitemid 27272413)
10. Coukos G,Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res. 2000;6:3342-3353. (Pubitemid 30637766)
11. Toyoizumi T, Mick R, Abbas AE, Kang AE, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex type 1 ICP34.5 mutant (HSV1716) in human non small cell lung cancer. Hum Gene Ther. 1999;10:3013-3029.
12. Thomas DL, Fraser NW. HSV-1 therapy of primary tumours reduces the number of metastases in an immune competent model of metastatic breast cancer. Mol Ther. 2003;8:543-551. (Pubitemid 37321682)
13. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication competent herpes simplex virus (ICP34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000;7:859-866. (Pubitemid 30303583)
14. Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP34.5-) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: proof of principle study. Gene Ther. 2002;9:398-406. (Pubitemid 34414038)
15. Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high grade glioma: safety data and long term survival. Gene Ther. 2004;11:1648-1658. (Pubitemid 39530101)
16. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet. 2001;357:525-526. (Pubitemid 32173591)
17. Mace AT, Ganly I, Soutar DS, et al. Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck. 2008;30:1045-1051.
18. Boyd M, Mairs RJ, Mairs SC, et al. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131]MIBG and clonogenic cell kill. Oncogene. 2001;20:7804-7808. (Pubitemid 33121954)
19. 131I]meta- iodobenzylguanidine and topotecan combination treatment of tumours expressing the noradrenaline transporter. Clin Cancer Res. 2005;11:7929-7937.
20. Boyd M, Mairs SC, Stevenson K, et al. Transfectant mosaic spheroids: a new model for the evaluation of bystander effects in experimental gene therapy. J Gene Med. 2002;4:567-576. (Pubitemid 40268383)
21. Mothersill C, Seymour CB. Radiation induced bystander effects: past history and future directions. Radiat Res. 2001;155:759-767. (Pubitemid 32494601)
22. Carlsson J, Aronsson EF, Hietala S-O, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol. 2003;66:107-117. (Pubitemid 36321806)
23. Quigg M, Mairs RJ, Brown SM, et al. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. Med Chem. 2005;1:423-429.
24. Harland J, Brown SM. HSV growth, preparation, and assay. In: Brown SM, MacLean AR, eds. Methods in Molecular Medicine - Herpes Simplex Virus Protocols. Totowa, N.J.: Humana Press Inc.; 1997:1-8.
25. 123I]MIBG. J Labelled Comp Radiopharm. 1999;42:653-661.
26. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer. 1998;77:1-10. (Pubitemid 28029765)
27. Morton DB, Griffiths PHM. Endpoints in animal study protocols. Vet Rec. 1985;116:431-436.
28. Braidwood L, Dunn PD, Hardy S, Evens TR, Brown SM. Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. Anticancer Res. 2009;29:2159-2166.
29. Mairs RJ, Boyd M. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy. Nucl Med Biol. 2008;35(suppl 1):S9-S20.
30. Asada T. Treatment of human cancer with mumps virus. Cancer. 1974;34:1907-1928.
31. McKie EA, Hope RG, Brown SM, MacLean AR. Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RL1 and its expression in a bacterial system. J Gen Virol. 1994;75:733-741. (Pubitemid 24118106)
32. Hammill AM, Conner J, Cripe TC. Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer. 2010;55:1253-1263.
33. Mace AT, Harrow SJ, Ganly I, Brown SM. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Acta Otolaryngol. 2007;127:880-887. (Pubitemid 47344054)
34. Guffey MB, Parker JN, Luckett WS, et al. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther. 2007;14:45-56. (Pubitemid 44952233)
35. Dai MH, Zamarin D, Gao SP, et al. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br J Surg. 2010;97:1385-1394.
36. Jarnagin WR, Zager JS, Hezel M, et al. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther. 2006;13:326-334. (Pubitemid 43255770)
37. Blank SV, Rubin SC, Coukos G, Amin KM, Albelda SM, Molnar-Kimber KL. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low dose radiation. Hum Gene Ther. 2002;13:627-639. (Pubitemid 34264313)
38. Advani SJ, Sibley GS, Song PY, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 1998;5:160-165. (Pubitemid 28077742)
39. Adusumilli PS, Stiles BM, Chan MK, et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann Thorac Surg. 2005;80:409-416.